Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have earned an average rating of “Moderate Buy” from the six brokerages that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $39.00.

A number of research firms have commented on ARTV. Needham & Company LLC reiterated a “buy” rating and set a $41.00 price objective on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. HC Wainwright increased their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Finally, Wedbush increased their price target on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th.

Insider Transactions at Artiva Biotherapeutics

In other news, Director Ra Capital Management, L.P. bought 24,944 shares of Artiva Biotherapeutics stock in a transaction on Friday, July 31st. The shares were bought at an average price of $9.93 per share, with a total value of $247,693.92. Following the acquisition, the director directly owned 17,329,570 shares in the company, valued at approximately $172,082,630.10. This represents a 0.14% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders purchased a total of 1,965,251 shares of company stock worth $16,188,035 in the last 90 days. Corporate insiders own 1.80% of the company’s stock.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. 5AM Venture Management LLC acquired a new position in Artiva Biotherapeutics in the second quarter worth $22,827,049,000. Blue Owl Capital Holdings LP bought a new stake in Artiva Biotherapeutics during the second quarter valued at $8,483,000. BlackRock Inc. acquired a new stake in shares of Artiva Biotherapeutics during the second quarter worth $6,739,000. Citadel Advisors LLC raised its holdings in shares of Artiva Biotherapeutics by 419.3% during the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after purchasing an additional 644,658 shares during the period. Finally, Nantahala Capital Management LLC bought a new position in shares of Artiva Biotherapeutics in the 2nd quarter worth about $2,910,000,000.

Artiva Biotherapeutics Stock Down 0.1%

Shares of ARTV traded down $0.01 during trading on Monday, reaching $10.91. The company’s stock had a trading volume of 43,696 shares, compared to its average volume of 381,558. The company has a market cap of $533.63 million, a price-to-earnings ratio of -3.32 and a beta of 2.16. The company has a fifty day moving average of $10.17 and a two-hundred day moving average of $8.25. Artiva Biotherapeutics has a twelve month low of $2.22 and a twelve month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.63). As a group, equities analysts forecast that Artiva Biotherapeutics will post -2.62 EPS for the current fiscal year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.